EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use

Pushkar Aggarwal, Denise Clark, Aatman Shah, Kyle Rismiller, Scott A Neltner

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2024.0390 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Pushkar Aggarwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Keratoacanthoma, Skin Neoplasms, Carcinoma, Squamous Cell, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This cross-sectional study assesses risk of dermatological immune-related adverse events associated with immunotherapy for cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KeratoacanthomaSkin NeoplasmsCarcinoma, Squamous CellImmune Checkpoint InhibitorsHumansMaleAgedB7-H1 AntigenFemaleProgrammed Cell Death 1 ReceptorMiddle Aged

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Zitieren

APA

Aggarwal, P., Clark, D., Shah, A., Rismiller, K., & Neltner, S. A. (2024). Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.0390

Vancouver

Aggarwal P, Clark D, Shah A, Rismiller K, Neltner SA. Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.0390

BibTeX
@article{Aggarwal2024,
  author = {Aggarwal, Pushkar and Clark, Denise and Shah, Aatman and Rismiller, Kyle and Neltner, Scott A},
  title = {Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2024.0390}
}
Kostenlos starten →